Population-based laboratory surveillance for tribe proteeae isolates in a large Canadian health region

Clinical Microbiology and Infection

Volumn 13, Issue 7, 2007, Pages 683-688

  Laupland, K B ^a,b,c   Parkins, M D ^a   Ross, T ^b,c   Pitout, J D D ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY HEALTH REGION   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Incidence; Laboratory surveillance; Proteeae; Proteus mirabilis; Risk factors; Susceptibility

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFAZOLIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CANADA; FEMALE; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RISK; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MORGANELLA; NONHUMAN; NURSING HOME PATIENT; OUTPATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA; RISK FACTOR;

MIRABILIS; PROTEUS MIRABILIS; PROVIDENCIA;

EID: 34250311683     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01715.x     Document Type: Article

References (22)

1. O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev 2000; 13: 534-546.
2. Tucci V, Isenberg HD. Hospital cluster epidemic with Morganella morganii. J Clin Microbiol 1981; 14: 563-566.
3. Muder RR, Brennen C, Wagener MM, Goetz AM. Bacteremia in a long-term-care facility: A five-year prospective study of 163 consecutive episodes. Clin Infect Dis 1992; 14: 647-654.
4. Warren JW. Providencia stuartii: A common cause of antibiotic-resistant bacteriuria in patients with long-term indwelling catheters. Rev Infect Dis 1986; 8: 61-67.
5. Kocka FE, Srinivasan S, Mowjood M, Kantor HS. Nosocomial multiply resistant Providencia stuartii: A long-term outbreak with multiple biotypes and serotypes at one hospital. J Clin Microbiol 1980; 11: 167-169.
6. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Clonal occurrences of multidrug-resistant Gram-negative bacilli: Report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). Diagn Microbiol Infect Dis 2006; 54: 249-257.
7. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: Risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005; 49: 2598-2605.
8. Woods TD, Watanakunakorn C. Bacteremia due to Providencia stuartii: review of 49 episodes. S Med J 1996; 89: 221-224.
9. McDermott C, Mylotte JM. Morganella morganii: Epidemiology of bacteremic disease. Infect Control 1984; 5: 131-137.
10. de Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: A two year survey. J Antimicrob Chemother 2000; 45: 537-539.
11. Kim BN, Kim NJ, Kim MN, Kim YS, Woo JH, Ryu J. Bacteraemia due to tribe Proteeae: A review of 132 cases during a decade (1991-2000). Scand J Infect Dis 2003; 35: 98-103.
12. Schuchat A, Hilger T, Zell E et al. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 2001; 7: 92-99.
13. Laupland KB. Population-based epidemiology of intensive care: Critical importance of ascertainment of residency status. Crit Care 2004; 8: R431-R436.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement, M100-S15. Wayne, PA: CLSI, 2005.
15. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187: 1452-1459.
16. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
17. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas County, Texas: Results from population-based surveillance in 1995. Clin Infect Dis 1998; 26: 590-595.
18. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: A 5 year population-based assessment. J Antimicrob Chemother 2005; 56: 532-537.
19. Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005; 43: 2844-2849.
20. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
21. Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli producing extended-spectrum beta-lactamases: Importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004; 38: 1736-1741.
22. Smellie WS, Clark G, McNulty CA. Inequalities of primary care microbiology testing between hospital catchment areas. J Clin Pathol 2003; 56: 933-936.